JP2005522432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005522432A5 JP2005522432A5 JP2003565480A JP2003565480A JP2005522432A5 JP 2005522432 A5 JP2005522432 A5 JP 2005522432A5 JP 2003565480 A JP2003565480 A JP 2003565480A JP 2003565480 A JP2003565480 A JP 2003565480A JP 2005522432 A5 JP2005522432 A5 JP 2005522432A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- composition according
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 239000002464 receptor antagonist Substances 0.000 claims 3
- 229940044551 receptor antagonist Drugs 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- LOCQRDBFWSXQQI-UHFFFAOYSA-N 5-chloro-n-(4-methoxy-3-piperazin-1-ylphenyl)-3-methyl-1-benzothiophene-2-sulfonamide Chemical group COC1=CC=C(NS(=O)(=O)C2=C(C3=CC(Cl)=CC=C3S2)C)C=C1N1CCNCC1 LOCQRDBFWSXQQI-UHFFFAOYSA-N 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- ATKZKAYWARYLBW-UHFFFAOYSA-N n-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide Chemical group COC1=CC=C(S(=O)(=O)NC=2C(=C(Cl)C=C(Cl)C=2)OC)C=C1N1CCNCC1 ATKZKAYWARYLBW-UHFFFAOYSA-N 0.000 claims 1
- 230000007514 neuronal growth Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0202680A GB0202680D0 (en) | 2002-02-05 | 2002-02-05 | Novel method |
| GB0222616A GB0222616D0 (en) | 2002-09-30 | 2002-09-30 | Novel method |
| PCT/GB2003/000462 WO2003066056A1 (en) | 2002-02-05 | 2003-02-04 | Method of promoting neuronal growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005522432A JP2005522432A (ja) | 2005-07-28 |
| JP2005522432A5 true JP2005522432A5 (enExample) | 2006-03-16 |
Family
ID=27736189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565480A Withdrawn JP2005522432A (ja) | 2002-02-05 | 2003-02-04 | ニューロン成長の促進方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070270432A1 (enExample) |
| EP (1) | EP1471912A1 (enExample) |
| JP (1) | JP2005522432A (enExample) |
| AU (1) | AU2003244452A1 (enExample) |
| WO (1) | WO2003066056A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7452888B2 (en) | 2002-03-27 | 2008-11-18 | Glaxo Group Limited | Quinoline derivatives and their use as 5-ht6 ligands |
| EA009367B1 (ru) | 2002-12-18 | 2007-12-28 | Сувен Лайф Сайенсиз Лимитед | ПРОИЗВОДНЫЕ 5-ТИА-5-ДИОКСО-4b-АЗАИНДЕНО[2,1-a]ИНДЕНА, ОБЛАДАЮЩИЕ АФФИННОСТЬЮ К РЕЦЕПТОРУ СЕРОТОНИНА |
| BRPI0412263B1 (pt) | 2003-07-22 | 2019-10-15 | Arena Pharmaceuticals, Inc. | Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição |
| MXPA06007415A (es) | 2004-01-02 | 2007-01-26 | Suven Life Sciences Ltd | Inden [2, 1a] indenos e isoindol [2,1-a] indoles novedosos. |
| US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| KR101016972B1 (ko) | 2005-08-12 | 2011-02-25 | 수벤 라이프 사이언시스 리미티드 | 기능성 5-ｈｔ6 리간드인 아미노아릴 설폰아미드 유도체 |
| WO2007020654A1 (en) | 2005-08-16 | 2007-02-22 | Suven Life Sciences | An improved process for the preparation of losartan |
| CA2670717C (en) | 2007-01-08 | 2012-01-10 | Suven Life Sciences Limited | 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands |
| US20080176861A1 (en) | 2007-01-23 | 2008-07-24 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| SI2155674T1 (sl) | 2007-05-03 | 2011-10-28 | Suven Life Sciences Ltd | Aminoalkoksi aril sulfonamid spojine in njih uporaba kot 5-ht6 ligandi |
| MX2010003765A (es) | 2007-10-26 | 2010-04-30 | Suven Life Sciences Ltd | Compuestos de aminoarilsulfonamida y su uso como ligandos de la 5-hidroxitriptamina6. |
| EP2254564A1 (en) | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010032257A1 (en) | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands |
| MX2011002884A (es) | 2008-09-17 | 2011-04-21 | Suven Life Sciences Ltd | Compuestos de aril-sulfonamida-amina y su uso como ligandos de 5-ht6. |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| WO2011083487A1 (en) | 2010-01-05 | 2011-07-14 | Suven Life Sciences Limited | Sulfone compounds as 5-ht6 receptor ligands |
| KR101608499B1 (ko) | 2013-10-08 | 2016-04-01 | 이화여자대학교 산학협력단 | 4-니트로인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 5-ht6 수용체 관련 질환의 예방 또는 치료용 약학적 조성물 |
| WO2016201373A1 (en) | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
| CA2992518A1 (en) | 2015-07-15 | 2017-01-19 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
-
2003
- 2003-02-04 US US10/503,679 patent/US20070270432A1/en not_active Abandoned
- 2003-02-04 EP EP03737355A patent/EP1471912A1/en not_active Withdrawn
- 2003-02-04 WO PCT/GB2003/000462 patent/WO2003066056A1/en not_active Ceased
- 2003-02-04 JP JP2003565480A patent/JP2005522432A/ja not_active Withdrawn
- 2003-02-04 AU AU2003244452A patent/AU2003244452A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005522432A5 (enExample) | ||
| HRP20161657T1 (hr) | Kinazolinoni kao inhibitori humane fosfatidilinozitol 3- kinaze delta | |
| MY148487A (en) | Biphenyl derivatives | |
| CA2364718A1 (en) | Monoamine reuptake inhibitors for treatment of cns disorders | |
| JP2006526031A5 (enExample) | ||
| MY130803A (en) | New quinuclidine amide derivatives | |
| WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
| GEP20094723B (en) | Tetraazabenzo [e] azulene derivatives and analogs thereof | |
| JP2007521280A5 (enExample) | ||
| NO20050883D0 (no) | Ny fremgangsmate for syntesen (IS)-4,5-dimetoksy-1-(metylaminometyl)-benzocyklobutan og addisjonssalter derav, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre | |
| ATE442135T1 (de) | 5ht2c-rezeptor-modulator-zusammensetzungen und anwendungsverfahren | |
| EP2397476A3 (en) | Indole derivative having PGD2 receptor antagonist activity | |
| EP1741712A3 (en) | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol | |
| JP2005504782A5 (enExample) | ||
| FR2882556B1 (fr) | Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
| CA2522813A1 (en) | 2-alkynyl-and 2-alkenyl-pyrazolo-¬4,3-e|-1,2,4-triazolo-¬1,5-c|-pyrimidine adenosine a2a receptor antagonists | |
| JP2008513510A5 (enExample) | ||
| WO2006066173A3 (en) | Novel mch receptor antagonists | |
| JP2004532828A5 (enExample) | ||
| WO2007039462A3 (en) | Indane derivatives as mch receptor antagonists | |
| RU2000100362A (ru) | Применение специфического антагониста 5нт2 рецепторов для приготовления лекарств, пригодных для лечения синдрома апноэ во сне | |
| NO20050888D0 (no) | Ny fremgangsmate for syntesen av 1,3,4,5-tetrahydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre | |
| SE0401655D0 (sv) | New compounds | |
| NO20063602L (no) | Benzyl(iden)-laktam-derivater | |
| DE60311942D1 (de) | Verfahren für die Synthese von Perindopril und seiner pharmazeutischen annehmbaren Salzen |